DaVita Inc. (NYSE:DVA) Stake Trimmed by Vanguard Group Inc.

Vanguard Group Inc. lowered its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,214,815 shares of the company's stock after selling 170,752 shares during the quarter. Vanguard Group Inc. owned approximately 6.36% of DaVita worth $779,876,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in DVA. SBI Securities Co. Ltd. acquired a new stake in shares of DaVita in the 4th quarter valued at about $41,000. Quarry LP acquired a new stake in DaVita during the third quarter valued at approximately $60,000. Venturi Wealth Management LLC lifted its holdings in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after buying an additional 152 shares during the last quarter. Versant Capital Management Inc grew its position in shares of DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of DaVita by 39.7% in the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after acquiring an additional 131 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on DVA shares. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a report on Wednesday. Barclays raised their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $166.33.

Remove Ads

DaVita Price Performance

DaVita stock traded down $0.50 during trading hours on Thursday, hitting $153.79. 882,428 shares of the company traded hands, compared to its average volume of 810,046. The firm's 50-day simple moving average is $156.16 and its two-hundred day simple moving average is $157.39. The firm has a market cap of $12.30 billion, a P/E ratio of 14.32, a P/E/G ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.